(SUPN) |
| 0 (0%) 01-13 19:36 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 61.32 |
| Resistance 1: | 52.50 |
| Pivot price: | 50.79 |
| Support 1: | 48.09 |
| Support 2: | 45.36 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -0.340 |
| Book Value | 18.380 |
| PEG Ratio | 0.00 |
| Gross Profit | 10.562 |
| Profit Margin (%) | -2.80 |
| Operating Margin (%) | 4.41 |
| Return on Assets (ttm) | 1.5 |
| Return on Equity (ttm) | -1.9 |
Company news
Fri, 09 Jan 2026
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Thu, 08 Jan 2026
Is Supernus Pharmaceuticals (SUPN) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Tue, 06 Jan 2026
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Fri, 19 Dec 2025
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Yahoo Finance
Fri, 19 Dec 2025
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Wed, 17 Dec 2025
Supernus Pharmaceuticals (SUPN): Assessing Valuation After a 33% One-Year Return and Undervalued Narrative - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
